City of Hope | Strategic Alliance Partners

January 19, 2024

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

January 17, 2024

Tycel Phillips, MD, discusses the potential advantages of treating patients with relapsed/refractory mantle cell lymphoma in the phase 3 GLOBRYTE trial.

January 15, 2024

Sumanta Kumar Pal, MD, FASCO, discusses the rationale for treating patients with zanzalintinib in relapsed/refractory clear cell renal cell carcinoma.

January 15, 2024

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

January 15, 2024

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

January 15, 2024

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

January 12, 2024

Tycel Phillips, MD, discusses the rationale for the phase 3 GLOBRYTE trial examining glofitamab in patients with relapsed/refractory mantle cell lymphoma.

January 12, 2024

Alexey Danilov, MD, PhD, discusses how further research may address unmet needs in chronic lymphocytic leukemia or mantle cell lymphoma.

December 31, 2023

Dedication to his patients and the field of hematology spanning decades has led Stephen J. Forman, MD, to break down barriers for treating patients with leukemia and lymphoma.

December 27, 2023

Maurie Markman, MD, highlights inroads made with immunotherapy, antibody-dependent cytotoxic agents, and molecular testing across oncology.

December 25, 2023

In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.

December 22, 2023

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

December 22, 2023

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

December 18, 2023

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.

December 18, 2023

In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.

December 15, 2023

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

December 14, 2023

A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.

December 12, 2023

Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.

December 12, 2023

NX-2127 showcased early efficacy in the form of responses with an acceptable toxicity profile in patients with relapsed or refractory B-cell malignancies, according to data from the ongoing phase 1 NX-2127-001 trial.

December 11, 2023

In this seventh episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss how artificial intelligence tools may be utilized to improve wait time for treatment, to provide more time for provider-patient interactions, and more.